Form 4: Macrogenics GC Granted 30,000 Stock Options

Macrogenics Senior VP and General Counsel Jeffrey Stuart Peters was granted 30,000 employee stock options with an exercise price of $1.58.

Summary

• Jeffrey Stuart Peters, Senior VP and General Counsel of Macrogenics Inc. (MGNX), was granted 30,000 employee stock options.
• The options have an exercise price of $1.58 per share.
• The grant date for these options is August 15, 2025.
• Vesting of the options will commence one year after the grant date, with 25% becoming exercisable.
• The remaining 75% of the options will vest in 12 substantially equal quarterly installments thereafter.
• The options are set to expire on August 15, 2035.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of stock options is a standard compensation practice, aligning executive incentives with shareholder value. It indicates ongoing executive retention and incentive programs, which is generally a stable sign.

Positives

• The grant of stock options aligns the interests of the Senior VP and General Counsel with those of shareholders, incentivizing long-term company performance.
• The options have a long expiration date of 10 years, providing ample time for potential value realization.

Negatives

• No immediate negative financial impact is associated with this option grant, as it is a compensation event rather than a sale or liability.

Risks

• The ultimate value of the granted options is contingent upon Macrogenics Inc.'s common stock price exceeding the $1.58 exercise price in the future.
• Future volatility in the company's stock price could impact the realized value of these options for the executive.

Future Outlook

The grant of stock options with a future vesting schedule indicates a long-term incentive strategy for the Senior VP and General Counsel, aiming to align their future performance with the company's growth and shareholder value creation. The options will vest over a period starting one year after the grant date, with the majority vesting quarterly thereafter.

Industry Context

Executive stock option grants are a standard component of compensation packages across the biotechnology and pharmaceutical industries. This practice aims to retain key talent and incentivize long-term performance, consistent with typical compensation structures for senior executives in publicly traded companies.

Comparison to Industry Standards

• Executive compensation structures, including stock option grants, are common across the biotech sector. While specific grant sizes vary based on company size, executive role, and performance, a grant of 30,000 options for a Senior VP and General Counsel at a company like Macrogenics (MGNX) is within the expected range for incentivizing long-term commitment and performance.
• No specific comparable companies, projects, or results were mentioned in the filing to provide a direct, detailed comparison.

Related Party Transactions

• The grant of 30,000 employee stock options to Jeffrey Stuart Peters, a Senior VP and General Counsel, constitutes a related party transaction as it involves compensation from the company to an executive.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential benefit from incentivized management performance aimed at increasing shareholder value.
• Employees: This executive compensation action signals standard practices for retaining key talent and competitive remuneration within the company.

Next Steps

• The first tranche of 25% of the options will vest and become exercisable on August 15, 2026.
• The remaining 75% of the options will vest in 12 substantially equal quarterly installments following the initial vesting date.

Key Dates

Keywords

Macrogenics, MGNX, Stock Options, Executive Compensation, SEC Form 4, Insider Transaction, Jeffrey Stuart Peters, General Counsel